STI571 (Gleevec™) as a paradigm for cancer therapy

Brian J. Druker

doi:10.1016/S1471-4914(02)02305-5

STI571 (Gleevec™) as a paradigm for cancer therapy

Brian J. Druker

Knight Cancer Institute

Research output: Contribution to journal › Review article › peer-review

263 Scopus citations

Abstract

STI571 (Gleevec™, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection and possible mechanisms of resistance to STI571. Finally, the potential use of STI571 with different tumors and the translation of this paradigm to other malignancies are explored.

Original language	English (US)
Pages (from-to)	S14-S18
Journal	Trends in Molecular Medicine
Volume	8
Issue number	4 SUPPL.
DOIs	https://doi.org/10.1016/S1471-4914(02)02305-5
State	Published - 2002

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology

Access to Document

10.1016/S1471-4914(02)02305-5

Cite this

@article{a1c87f71d3204cbd8da2f2d12614fd6c,

title = "STI571 (Gleevec{\texttrademark}) as a paradigm for cancer therapy",

abstract = "STI571 (Gleevec{\texttrademark}, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection and possible mechanisms of resistance to STI571. Finally, the potential use of STI571 with different tumors and the translation of this paradigm to other malignancies are explored.",

author = "Druker, {Brian J.}",

note = "Funding Information: B.J.D. is funded by grants from the NCI, a Specialized Center of Research Award from The Leukemia and Lymphoma Society, a Clinical Scientist Award from the Burroughs Wellcome Fund and the T.J. Martell Foundation.",

year = "2002",

doi = "10.1016/S1471-4914(02)02305-5",

language = "English (US)",

volume = "8",

pages = "S14--S18",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Limited",

number = "4 SUPPL.",

}

TY - JOUR

T1 - STI571 (Gleevec™) as a paradigm for cancer therapy

AU - Druker, Brian J.

N1 - Funding Information: B.J.D. is funded by grants from the NCI, a Specialized Center of Research Award from The Leukemia and Lymphoma Society, a Clinical Scientist Award from the Burroughs Wellcome Fund and the T.J. Martell Foundation.

PY - 2002

Y1 - 2002

N2 - STI571 (Gleevec™, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection and possible mechanisms of resistance to STI571. Finally, the potential use of STI571 with different tumors and the translation of this paradigm to other malignancies are explored.

AB - STI571 (Gleevec™, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection and possible mechanisms of resistance to STI571. Finally, the potential use of STI571 with different tumors and the translation of this paradigm to other malignancies are explored.

UR - http://www.scopus.com/inward/record.url?scp=0036216405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036216405&partnerID=8YFLogxK

U2 - 10.1016/S1471-4914(02)02305-5

DO - 10.1016/S1471-4914(02)02305-5

M3 - Review article

C2 - 11927282

AN - SCOPUS:0036216405

SN - 1471-4914

VL - 8

SP - S14-S18

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 4 SUPPL.

ER -

STI571 (Gleevec™) as a paradigm for cancer therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this